Tags

Type your tag names separated by a space and hit enter

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020 03; 30(3):269-271.CR

Links

Publisher Full Text
ncbi.nlm.nih.gov
dx.doi.org
PMC Free PDF

Authors+Show Affiliations

Wang M
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
Cao R
National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China.
Zhang L
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
Yang X
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
Liu J
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
Xu M
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
Shi Z
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
Hu Z
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China. huzh@wh.iov.cn.
Zhong W
National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China. zhongwu@bmi.ac.cn.
Xiao G
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China. xiaogf@wh.iov.cn.

MeSH

Adenosine MonophosphateAlanineAnimalsAntimalarialsAntiviral AgentsBetacoronavirusBiological AssayChlorocebus aethiopsChloroquineCoronavirus InfectionsDrug DiscoveryDrug Evaluation, PreclinicalHumansMiddle East Respiratory Syndrome CoronavirusPneumonia, ViralSARS VirusSincalideVero Cells

Pub Type(s)

Letter
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32020029

Clinical Trial Links

The Vietnam Chloroquine Treatment on COVID-19
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19
Trial of Imatinib for Hospitalized Adults With COVID-19
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
Primary Prevention of Infection by COVID-19 in Health Providers
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
Clinical Trial of Favipiravir Treatment of Patients With COVID-19
Hydroxychloroquine, Azithromycin and Zinc for the Treatment of COVID-19 in the Outpatient Setting
Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)

Citation

Wang, Manli, et al. "Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro." Cell Research, vol. 30, no. 3, 2020, pp. 269-271.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269-271. https://doi.org/10.1038/s41422-020-0282-0
Wang M, et al. Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. Cell Res. 2020;30(3):269-271. PubMed PMID: 32020029.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. AU - Wang,Manli, AU - Cao,Ruiyuan, AU - Zhang,Leike, AU - Yang,Xinglou, AU - Liu,Jia, AU - Xu,Mingyue, AU - Shi,Zhengli, AU - Hu,Zhihong, AU - Zhong,Wu, AU - Xiao,Gengfu, Y1 - 2020/02/04/ PY - 2020/01/25/received PY - 2020/01/28/accepted PY - 2020/2/6/pubmed PY - 2020/3/24/medline PY - 2020/2/6/entrez SP - 269 EP - 271 JF - Cell research JO - Cell Res. VL - 30 IS - 3 SN - 1748-7838 UR - https://www.unboundmedicine.com/medline/citation/32020029/full_citation L2 - http://dx.doi.org/10.1038/s41422-020-0282-0 DB - PRIME DP - Unbound Medicine ER -